What question did this study set out to answer?

The study aims to evaluate the effects of tocilizumab for cytokine release syndrome in patients undergoing allogeneic hematopoietic stem cell transplantation.

December 8, 2025Blood

Tocilizumab for cytokine release syndrome after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide

View Full Paper

Ask AI

Bookmark

Authors

EBEvandro D. BezerraCleveland Clinic HCHannah ChoeThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute NDNathan DenlingerThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Discussion

Member takes

Implication

Retrospective study shows tocilizumab lowers graft-versus-host disease in transplant patients with cytokine release syndrome, indicating improved management of CRS.

Key Points

The study aims to evaluate the effects of tocilizumab for cytokine release syndrome in patients undergoing allogeneic hematopoietic stem cell transplantation.
Conducted a retrospective study of adult patients undergoing PTCy-based alloHCT
Patients with cytokine release syndrome were analyzed based on tocilizumab use
Performed 1:1 propensity score matching to control confounding variables
Analyzed engraftment, non-relapse mortality, and graft-versus-host disease using competing risk models
190 out of 346 patients developed cytokine release syndrome
Tocilizumab use was associated with shorter cytokine release syndrome duration
Tocilizumab significantly reduced the incidence of acute and chronic graft-versus-host disease
Higher rates of bacterial infections were observed in patients receiving tocilizumab

Cite This Study

Bezerra et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d864 https://doi.org/10.1182/blood-2025-4217

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study shows tocilizumab lowers graft-versus-host disease in transplant patients with cytokine release syndrome, indicating improved management of CRS.

Tocilizumab for cytokine release syndrome after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide

Discussion

Member takes

Implication

Key Points

Cite This Study

Tocilizumab for cytokine release syndrome after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider